City of Hope, the world-renowned independent research and cancer and diabetes treatment organisation, and leading biomedical research institute Translational Genomics Research Institute (TGen), have announced that they have formed an alliance "to make precision medicine a reality for patients".
According to a joint press statement: "This alliance enables both institutes to complement each other in their common areas of research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen."
City of Hope is a pioneer in the fields of bone marrow transplantation, haematologic malignancies, and select solid tumours and diabetes. TGen is a leader in applying genomic analysis and bioinformatics to cancer drug development. Together, City of Hope and TGen say they will transform the diagnosis, treatment and prevention of cancer and other life-threatening diseases with the alliance accelerating the speed with which scientists and medical staff convert research discoveries into cures for patients.
“Patients want choices and access to the newest and most advanced care available,” said City of Hope CEO Robert Stone. “City of Hope and TGen share a common vision for improving patient outcomes, and our collaboration will speed cancer cures by rapidly advancing discoveries to define high-risk populations, identifying targets for prevention and treatment, and promoting initiatives that close health equity gaps.”
TGen CEO Jeffrey Trent added: “This alliance will enable us to fully deploy genomic-enabled medicine within a modern health care system to create a disruptive change in the practice of medicine. Our aim is to not only navigate this changing field, but lead it.”
Duarte (CA) and Phoenix (AZ), USA